Venetoclax( Venclyxta)

[Drug Name]

Generic Name: Vinacrine Tablets

Trade name: VENCLEXTA

English name: Venetoclax Tablets

Hanyu Pinyin: Weinaikela Pian

[Indications

This product is used in combination with azacitidine for the treatment of newly diagnosed adult patients with acute myeloid leukemia who are not candidates for strong induction chemotherapy due to comorbidities, or who are 75 years of age and older.

[Usage and dosage]

Days 1-3 of the 1st course of treatment are dose creep.

Day 1, 100 mg

Day 2, 200 mg

Day 3, 400 mg

Day 4 and beyond, 400mg once a day for 28 days per course of treatment

On days 1-7 of each course of treatment, this product is to be used in combination with azacitidine, which is administered subcutaneously at a dose of 75 mg/m2.

[Adverse Reaction]

The most common adverse reactions (≥30%, any grade) were nausea, diarrhea, constipation, neutropenia, thrombocytopenia, hemorrhage, peripheral edema, vomiting, fatigue, febrile neutropenia, rash, and anemia.

Serious adverse reactions were reported in 75% of patients. The most common serious adverse reactions (≥5%) were febrile neutropenia, pneumonia (excluding fungal pneumonia), sepsis (excluding fungal sepsis), respiratory failure, and multiple organ dysfunction syndrome.

[Storage]

Seal and store at no more than 30°C.